TUCSON , April 29,
2022 /PRNewswire/ -- Accelerate Diagnostics, Inc.
(NASDAQ: AXDX) announced today that management will host a
conference call on Monday, May 16,
2022, at 4:30 p.m. Eastern
Time to review 2022 first quarter results.
To listen to the audio webcast online, visit ir.axdx.com. A
replay of the audio webcast will be available until August 15,
2022.
To listen by phone, dial +1.877.883.0383 and enter the Elite
Entry Number: 0355137. International participants may dial
+1.412.902.6506. Please dial in 10-15 minutes prior to the start of
the conference.
A replay of the call will be available by telephone at
+1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the
replay code 5137603 until June 6, 2022.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics
company dedicated to providing solutions for the global challenges
of antimicrobial resistance and sepsis. The Accelerate Pheno®
system and Accelerate Arc™ system are designed to reduce the time
clinicians must wait to determine the most optimal antibiotic
therapy for bacteremic patients. These diagnostic systems are
designed to serve clinical laboratories with automated solutions to
expedite time to identification and antimicrobial susceptibility
test (AST) results directly from positive blood culture samples.
Multiple external studies have proven that Accelerate solutions
deliver results 1 to 2 days faster than existing methods, enabling
clinicians to optimize antibiotic selection and dosage specific to
the individual patient's infection, days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and
"ACCELERATE PHENOTEST" and diamond shaped logos and marks are
registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
SOURCE Accelerate Diagnostics, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2022-first-quarter-results-301536020.html
SOURCE Accelerate Diagnostics, Inc.